Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 9/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 2/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6294696 | 0.88 | AR (0.55) | ARGAAALDH1A1SLC6A4CYP2A6 | |
| SCHEMBL6294693 | 0.83 | AR (0.50) | ARALDH1A1PDE4BSLC6A4SLC6A2 | |
| SCHEMBL6295751 | 0.78 | MERTK (0.52) | ARALDH1A1TBXA2R | |
| SCHEMBL860477 | 0.77 | PARP15 (0.49) | ARGAARCE1ALDH1A1PDE4B | |
| SCHEMBL10999189 | 0.76 | TEAD4 (0.54) | ARGAARCE1ALDH1A1 | |
| SCHEMBL806471 | 0.76 | CYP2A6 (0.59) | ARALDH1A1SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL1104942 | 0.72 | CYP2A6 (0.54) | ARALDH1A1SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL922684 | 0.72 | AR (0.58) | ARGAAALDH1A1SLC6A4SLC6A2 | |
| SCHEMBL5583654 | 0.71 | TEAD4 (0.57) | ARGAARCE1ALDH1A1 | |
| SCHEMBL18852193 | 0.71 | CYP2A6 (0.52) | ARGAAALDH1A1CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6916837-B2 | Amidino derivatives and anticoagulants and thrombosis therapeutic agents containing them | EISAI CO., LTD. (JP) | 2005-07-12 | — | — | US | disclosed |
| US-20030181766-A1 | Amidino derivatives, and anticoagulants and thrombosis therapeutic agents containing them | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2003-09-25 | — | — | US | disclosed |
| EP-1312602-A1 | Amidino derivatives, and anticoagulants and thrombosis therapeutic agents containing them | Eisai Co., Ltd. (JP) | 2003-05-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181766-A1 | Amidino derivatives, and anticoagulants and thrombosis therapeutic agents containing them | F2, SERPINC1, F12 | AR 146/4885GAA 4143/4885RCE1 858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.